PTC596 is a cell-permeable small compound capable of inducing BMI1 protein proteosomal degradation at nanomolar concentrations.41 The compounds can cross the blood–brain barrier and is orally administrable.40 To evaluate its utility for brain cancer treatment, we exposed the patient-derived GBM0811 cell line maintained and grown as neurospheres to various concentrations of PTC596, or to A1016, a closely related molecule. Here, BMI1 is linked to brain cancer.